Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 367

Welcome to Firstlinks Edition 367

  •   22 July 2020
  • 1
  •      
  •   

Weekend market update: For the first time in a month, Wall Street lost ground last week on fears of technology stocks underperforming earnings estimates and escalations in COVID-19 statistics. The S&P/ASX200 lost 1.1% on Friday while the S&P500 shed 0.6%. Gold rose above US$1,900 for the first time since 2011, and the Australian dollar remained firm at US$0.71.

***

There is a similarity between the current health crisis and economic crises of the past. For COVID-19, record amounts of biotech funding from government agencies and private companies are looking for a vaccine. Likewise, central banks once struggled treating recessions but the 'vaccine' now is record amounts of financial stimulus to ensure liquidity. While the world awaits a COVID treatment, markets are purring along, at least until side effects hit.

In what is now considered a major economic policy mistake, during the Great Depression from 1930 to 1933, the US Fed shrank the supply of cash quickly, leaving less money in circulation and reducing liquidity for people to buy goods, services and assets. A potentially mild recession became severe with a quarter of Americans out of work. Disposable incomes fell by almost 30%.

Learning how to treat that disease, central banks now throw unlimited 'whatever it takes' liquidity at the market, the latest iteration being the US Fed buying corporate bonds. The chart below shows the total assets of the US Fed, currently US$7 trillion, with the 2020 expansion making the GFC look like a blip.

In the background, we have Modern Monetary Theory (MMT) saying governments have no practical constraints on their spending, so they can just go hard when there are no inflationary consequences. Next, solve world poverty?

In Australia, gross government debt has reached about $850 billion and where previously a budget surplus in 2019/20 was forecast, a $90 billion deficit is now expected. The spending has a purpose and Reserve Bank Governor, Philip Lowe, is relaxed on the amount. The combination of JobKeeper, JobSeeker, super early release and business loans has helped retail trade, as shown below from ABS data and CBA Economics.

Individuals and the economy are benefitting. The heavy retail fall in April was followed by strength in May and June, such that Q2 2020 was only 2% lower than Q1 2020, an extraordinary result given the job losses and lockups. Negative views on the state of the economy have fallen quickly. So far, that's the economic cure, although we have yet to see the reality of poor corporate earnings in the coming season.

As with a vaccine, it remains to be seen whether there are unacceptable side effects from burgeoning government debt, but after a dozen years of liquidity injections in the US, there are few signs of inflation or limits to the size of the Fed balance sheet.

Where are we on the other cure, the vaccine? The stock market has drawn considerable enthusiasm from potential breakthroughs by US company Moderna and the UK's AstraZeneca working with Oxford University. China's Sinovac, Australia's CSL, big US players such as Johnson & Johnson and Merck, and German firms CureVac and BioNtech are among the leaders.

However, there is a reality check on vaccines which the market is ignoring. Rod Skellet reports on the company with most recent vaccine success, Merck, saying it takes much longer to develop safely than the market recognises. After approval, will governments hang on to supplies for their own people?

Next up, two of Australia's highest-profile fund managers identify stocks they like in the current market. Matt Williams shows the value of clever capital allocation is vital for company success, and Paul Xiradis reveals his favourites.

Then Raewyn Williams describes the conditions under which value stocks can recover lost ground versus the growth momentum, while Christine Benz interviews retirement expert, Wade Pfau, on the 4% 'safe withdrawal' rule, which has long been an industry standard for not running out of money in retirement.

In these uncertain times, Noel Whittaker describes new ways a portfolio can be hedged against stock market falls, and Amit Lodha says his reading has informed his long-term thinking more than ever during the pandemic lockdown.

This week's White Paper from Fidelity International focusses on the rapid growth of waste, and the investment opportunities from avoiding a devastating impact on our lives and the planet.

Graham Hand, Managing Editor

Latest updates

PDF version of Firstlinks Newsletter

Australian ETF Review from Bell Potter (June 2020 update)

ASX Listed Bond and Hybrid rate sheet from NAB/nabtrade

Indicative Listed Investment Company (LIC) NTA Report from Bell Potter

LIC Monthly Report from Morningstar

Plus updates and announcements on the Sponsor Noticeboard on our website

 

banner

Most viewed in recent weeks

After 30 years of investing, I prefer to skip this party

Eventually, prices become so extreme they bear no relationship to reality, and a bubble forms. I believe we are there today, not for all stocks but for many in the technology space.

Australian house prices: Part 2, the bigger picture

There is good reason to believe the negatives will continue to outweigh the positives over the next 12 to 18 months. There is more concern about house prices than the short-term indicators suggest.

How to handle the riskiest company results in history

It is better to miss a results bounce and buy after the company has delivered than it is to step on a landmine. With such uncertainty, avoid FOMO by following these result season investing tips.

Australian house prices: Part 1, how worried should we be?

Three key indicators are useful for predicting the short-term outlook for house prices, although tighter lockdowns make the outlook gloomier. There is enough doubt to create cause for concern.

Welcome to Firstlinks Edition 367

There is a similarity between the current health crisis and economic crises of the past. For COVID-19, record amounts of biotech funding from government agencies and private companies are looking for a vaccine. Likewise, central banks once struggled treating recessions but the 'vaccine' now is record amounts of financial stimulus to ensure liquidity. While the world awaits a COVID treatment, markets are purring along, at least until side effects hit.

  • 22 July 2020

Welcome to Firstlinks Edition 369

Imagine you had perfect foresight about COVID-19 at the start of the year. You correctly foresaw that the global pandemic would kill over 700,000 among 20 million infections by August. In Australia, borders would close, cities would be locked down, most mortgagors would be on income support and companies would be allowed to trade while insolvent. You then had to guess how much the stock market would fall. Would you say about 10%?

  • 6 August 2020

Latest Updates

Shares

How to handle the riskiest company results in history

It is better to miss a results bounce and buy after the company has delivered than it is to step on a landmine. With such uncertainty, avoid FOMO by following these result season investing tips.

Shares

The rise of Afterpay and emergence of a new business model

Sometimes the simplest ideas are the best. The founders of Afterpay stumbled on the attraction for consumers of paying by instalments, and now retailers must offer the facility or lose business.

Property

WFH and its impact on Australian offices and tenants

Although most office workers are currently WFH, an energy and a buzz comes from working in the same physical space. Other benefits include team building, relationships, talent mentoring and creative collaboration.

Fixed interest

Why 2020 has been the year of the bond market

Going back to June 2019, investors would have questioned the logic of diversifying away from outperforming growth assets. But when markets feel at their best, it is paramount to keep a perspective on long-term goals.

Investment strategies

Is 5G all hype or real investable opportunity?

While its impact will take time to unfold, 5G will meaningfully change the world. Once adoption takes hold, there is huge potential for its application across a wide range of industries.

Property

Australian house prices: Part 1, how worried should we be?

Three key indicators are useful for predicting the short-term outlook for house prices, although tighter lockdowns make the outlook gloomier. There is enough doubt to create cause for concern.

Property

Australian house prices: Part 2, the bigger picture

There is good reason to believe the negatives will continue to outweigh the positives over the next 12 to 18 months. There is more concern about house prices than the short-term indicators suggest.

Sponsors

Alliances

© 2020 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use.
Any general advice or class service prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, has been prepared by without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.